2026

2026831

PR 52-Week Topline Results of Phase I/II Clinical Trial (LAPiS study) for Allogeneic iPS cell-derived Cardiomyocyte Spheroids (HS-001) Presented in Invited Lecture at ESC Congress 2026

2026723

Congress Keiichi Fukuda, CEO, to Present 52-Week Topline Results from the LAPiS Study in an Invited Lecture at the ESC Congress 2026

2026612

PR Heartseed, World's First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed

202668

Congress Keiichi Fukuda, CEO, to Speak at the 10th Cardiovascular Bioengineering (CVBE) Symposium 2026

2026216

PR Notice Regarding Selection as a Constituent of the JPX Start-Up Acceleration 100 Index

202629

Seminar Keiichi Fukuda, CEO, to Speak at The 21st Edition of Roundtable Japan

2026119

Congress Keiichi Fukuda, CEO, to Speak at Keystone Symposia "iPSCs: Progress, Opportunities, and Challenges"

1